Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort.

Guo, Yutao ORCID: 0000-0002-7626-7751, Zhang, Hui, Lip, Gregory YH ORCID: 0000-0002-7566-1626 and mAF-App II Trial investigators, (2022) Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort. JACC. Asia, 2 (6). pp. 737-746.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1016/j.jacasi.2022.07.006

Abstract

<h4>Background</h4>There are limited data on mobile health detection of prevalent atrial fibrillation (AF) and its related risk factors over time.<h4>Objectives</h4>This study aimed to report the trends on prevalent AF detection over time and risk factors, with a consumer-led photoplethysmography screening approach.<h4>Methods</h4>3,499,461 subjects aged over 18 years, who use smart devices (Huawei Technologies Co.) were enrolled between October 26, 2018, and December 1, 2021.<h4>Results</h4>Among 2,852,217 subjects for AF screening, 12,244 subjects (0.43%; 83.2% male, mean age 57 ± 15 years) detected AF episodes. When compared with 2018, the risk (adjusted HRs, 95% CI) for monitored prevalent AF increased significantly for subjects when monitoring started in 2020 (adjusted HR: 1.34; 95% CI: 1.27-1.40; <i>P</i> < .001) or in 2021 (adjusted HR: 1.67; 95% CI: 1.59-1.76; <i>P</i> < 0.001). Of the 961,931 subjects who screening for both AF and OSA, 18,032 (1.9%, 97.8% male, mean age 44 ±17 years) were identified as high risk for OSA, which resulted in a 1.5-fold increase (95% CI: 1.30-fold to 1.75-fold) in the prevalent AF. A total of 5,227 (53.3%, 5,227/9,797) subjects were effectively followed up, from which 4,903 (93.8%, 4,903/5,227) subjects were confirmed with the diagnosis of AF, by the mAFA Telecare Team health providers.<h4>Conclusions</h4>Photoplethysmography-based smart devices can facilitate screening for AF with >93% confirmation of detected AF episodes even for the low-risk general population, highlighting the increased risk for detecting prevalent AF and the need for modification of OSA that increase AF susceptibility. (Mobile Health [mHealth] Technology for Improved Screening, Patient Involvement and Optimizing Integrated Care in Atrial Fibrillation [mAFA (mAF-App) II study]; ChiCTR-OOC-17014138).

Item Type:	Article
Uncontrolled Keywords:	mAF-App II Trial investigators
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User:	Symplectic Admin
Date Deposited:	28 Sep 2023 13:36
Last Modified:	28 Sep 2023 13:36
DOI:	10.1016/j.jacasi.2022.07.006
Open Access URL:	https://doi.org/10.1016/j.jacasi.2022.07.006
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3173166